[Featured Stock] Hanmi Pharm, 3.57%↑ on 'Start of Clinical Trials for Next-Generation Immuno-Oncology Drug'

Hanmi Pharm's stock price is on the rise after starting the first human clinical trial of the next-generation immuno-oncology drug BH3120. As of 10:20 AM on the 20th, Hanmi Pharm is trading at 348,500 KRW, up 12,000 KRW (3.57%) compared to the previous trading day.

Hanmi Pharmaceutical Headquarters

The day before, Hanmi Pharm announced, "On the 13th, the first patient registration and dosing for the global Phase 1 clinical trial of BH3120 targeting patients with progressive or metastatic solid tumors was completed at a domestic university hospital." The Phase 1 trial is planned to be conducted simultaneously in Korea and the United States.

Regarding this, a Hanmi Pharm representative explained, "The BH3120 clinical trial is Hanmi's first project to conduct global clinical research using the proprietary bispecific antibody platform technology, Pentambody, in the immuno-oncology field that is changing the paradigm of cancer treatment."

On the same day, Jang Min-hwan, a researcher at Hi Investment & Securities, said, "The GLP1 agonist pipeline for obesity treatment and MASH (metabolic dysfunction-associated steatohepatitis) indications is entering its most notable period. With the first MASH treatment approval expected next month, the MASH market is set to open."

He added, "Since 2022, Hanmi Pharm has been strengthening evidence-based marketing capabilities by publishing research results on Rosuzet in major academic journals. This is expected to drive the sales growth of Rosuzet alongside its existing excellent sales force. Based on solid performance and the strong drive of the integrated holding company, expansion of R&D investment and long-term growth are anticipated."